Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has appointed Sidney Braun as the CEO of its subsidiary Liora Technologies Europe Ltd., aiming to advance cancer treatment technologies, particularly the LiGHT System for proton therapy [1][4]. Company Overview - LIXTE is a clinical-stage pharmaceutical and med-tech company focused on developing and commercializing cancer therapies, with its lead compound LB-100 showing promise in enhancing chemotherapy and immunotherapy outcomes [5]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [5]. Leadership Appointment - Sidney Braun brings over 20 years of operational and strategic experience in the healthcare industry, having played a significant role in the creation of Liora and the acquisition of its assets by LIXTE [2][3]. - Braun's commitment to advancing the radiotherapy segment aims to achieve positive patient outcomes and long-term shareholder value for LIXTE [4]. Technology Focus - Liora is developing electronically controlled proton therapy systems, with the LiGHT System believed to offer significant advantages over existing technologies for tumor treatment [6].

Company Overview - LIXTE Biotechnology Holdings Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly through its lead compound LB-100, which is a first-in-class PP2A inhibitor [9][10] - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [10] - LIXTE is also developing electronically controlled proton therapy systems through its subsidiary, Liora Technologies Europe Ltd., with its flagship technology, the LiGHT System, believed to offer significant advantages in tumor treatment [11] Event Details - The inaugural Good Health: Mind, Body & Soul Summit, sponsored by LIXTE, will take place on February 19, 2026, at Morehouse College in Atlanta, focusing on health equity for Black men and families [2][3] - The event is inspired by the music and legacy of De La Soul, aiming to connect health, culture, and science to promote wellness [4][5] - The Summit will feature discussions on various health topics, including cancer, heart disease, mental health, and intergenerational wellness, bringing together health experts, artists, and community leaders [5]

Core Insights - LIXTE Biotechnology Holdings, Inc. announced that findings published in the journal Nature validate its ongoing clinical trials with the proprietary compound LB100 for Ovarian and Colorectal cancers [1][2] Group 1: Clinical Trials and Research Findings - A study led by Dr. Amir Jazaeri found that Ovarian Clear Cell Carcinoma (OCCC) patients with inactivating mutations in PPP2R1A had significantly better overall survival when treated with immune checkpoint blockade therapy [2][3] - Inactivating mutations in PPP2R1A reduce the enzymatic activity of PP2A, which is the target of LIXTE's LB-100, and these tumors showed increased interferon gamma response pathways associated with improved immune checkpoint responses [3] - LIXTE is conducting two clinical trials to investigate LB-100's activity in combination with checkpoint immunotherapy, one in collaboration with GSK for OCCC and another with Roche for colon cancer patients [4][5] Group 2: Company Overview and Future Directions - LIXTE is focused on developing new cancer therapies and has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity [6][7] - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7]

Core Insights - LIXTE Biotechnology Holdings, Inc. has initiated two new clinical trials in collaboration with MD Anderson and the Netherlands Cancer Institute, focusing on treatments for ovarian and colorectal cancer [1][3] - The company has secured an exclusive patent license agreement with the NIH for LB-100, which aims to enhance cancer immunotherapies [1] - Recent publications in prominent medical journals EMBO and Cancer Discovery support LIXTE's clinical trial program, highlighting the potential of LB-100 in cancer treatment [1][6] Clinical Trials - LIXTE is conducting trials for ovarian cancer at M.D. Anderson Cancer Center and Northwestern University, with support from GSK [2][3] - A colorectal cancer trial is being conducted at the Netherlands Cancer Institute, supported by F. Hoffmann-La Roche [3][6] - The first patient has been dosed in a Phase 1b/2 trial combining LB-100 with GSK's immunotherapy for ovarian clear cell carcinoma [6] Intellectual Property and Research - LIXTE has received a Notice of Allowance from the USPTO for a patent related to the modulation of immune response using LB-100 [6] - Studies published in Cancer Discovery and EMBO indicate that LB-100 can alter cancer cells to enhance their vulnerability to immunotherapy [6] Financial Activities - The company completed a registered direct offering, raising approximately $1,050,000 for working capital and corporate purposes [6]